Clinical Metabolomics Inc. is using metabolomics to aid product discovery by finding disease-specific metabolite panels that monitor drug efficacy and provide insights about the mechanism of action of new products. Its most advanced tool can distinguish between diabetic kidney disease patients and healthy controls and could give companies faster readouts about how their investigational kidney drugs are working, and how well.

The idea for the panel came from work by ClinMet's scientific founder and SAB chair Kumar Sharma at the University of California, San Diego, who was searching for biomarkers to track diabetic kidney disease and determine why some patients are unresponsive to particular treatments. Sharma is director of the Center for Renal Translational Medicine and the Institute of Metabolomic Medicine at UCSD.